Cytosorbents Corp
CTSO
78 hedge funds and large institutions have $33.9M invested in Cytosorbents Corp in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 24 closing their positions.
43% more call options, than puts
Call options by funds: $63K | Put options by funds: $44K
5.9% less ownership
Funds ownership: 41.46% → 35.56% (-5.9%)
11% less funds holding
Funds holding: 88 → 78 (-10)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
42% less capital invested
Capital invested by funds: $58.8M → $33.9M (-$24.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.2M |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$574K |
| 3 |
E
Ergoteles
New York
|
+$465K |
| 4 |
SC
Skylands Capital
Milwaukee,
Wisconsin
|
+$452K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$386K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.26M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.3M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$769K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$668K |
| 5 |
Goldman Sachs
New York
|
-$558K |
CTSO Hedge Fund Activity: Q2 2022 in Review
78 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cytosorbents Corp (CTSO) for Q2 2022, worth a combined $33.9M — down 42% from $58.8M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CTSO and 16 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.2M. The largest seller was BlackRock, cutting an estimated $4.26M.
- 78 institutional investors held Cytosorbents Corp (CTSO) as of Q2 2022, down from 88 in Q1 2022.
- Funds reported $33.9M of Cytosorbents Corp stock for Q2 2022, down 42% quarter-over-quarter.
- 16 funds opened new Cytosorbents Corp positions in Q2 2022 and 24 closed out, a net change of -8 holders.
- The largest Cytosorbents Corp buyer in Q2 2022 was Millennium Management, an estimated $1.2M added.
- The largest Cytosorbents Corp seller in Q2 2022 was BlackRock, an estimated $4.26M sold.
Based on aggregated 13F filings for Q2 2022.